Publications 2025

Bergholtz H, Norum JH, Lien TG, Skrede ML, Garred Ø, Sørlie T (2025)
B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses
Breast Cancer Res, 27 (1), 44
DOI 10.1186/s13058-025-01990-2, PubMed 40119362

Fjørtoft MO, Garred Ø, Lingjærde OC, Lande KT, Ottestad L, Bergheim IR, OSBREAC, Lømo J, LaMont C, Myklebust JH, Russnes H, Huse K, Rye IH (2025)
Single-cell analysis reveals tumour size as a key driver of immune cell profile alterations in primary breast tumours and corresponding lymph nodes
BJC Rep, 3 (1), 35
DOI 10.1038/s44276-025-00152-3, PubMed 40394379

Røssevold AH, Tekpli X, Lingjærde OC, Russnes HG, Vallon-Christersson J, Borgen E, Lømo J, Garred Ø, Dorraji E, Kristensen VN, Naume B, Kyte JA (2025)
High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis
Commun Med (Lond), 5 (1), 234
DOI 10.1038/s43856-025-00865-z, PubMed 40523912

Publications 2024

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Eide NA, Faber RT, Garred Ø, Sørum Falk R, Robsahm TE (2024)
Characterizations of uveal melanoma patients with three additional primary malignancies
Acta Ophthalmol, 102 (6), 690-696
DOI 10.1111/aos.16631, PubMed 38229427

Kildal W, Cyll K, Kalsnes J, Islam R, Julbø FM, Pradhan M, Ersvær E, Shepherd N, Vlatkovic L, OSBREAC, Tekpli X, Garred Ø, Kristensen GB, Askautrud HA, Hveem TS, Danielsen HE, OSBREAC - Oslo Breast Cancer Consortium (2024)
Deep learning for automated scoring of immunohistochemically stained tumour tissue sections - Validation across tumour types based on patient outcomes
Heliyon, 10 (13), e32529
DOI 10.1016/j.heliyon.2024.e32529, PubMed 39040241

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Publications 2023

Navaratnam J, Faber R, Eide N, Lund-Iversen M, Garred Ø, Munier FL (2023)
Retinocytoma Undergoing Retinoblastoma Transformation in an Adult Patient
Case Rep Ophthalmol Med, 2023, 8127245
DOI 10.1155/2023/8127245, PubMed 37529687

Publications 2022

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

Publications 2021

Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A (2021)
RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer
Nat Commun, 12 (1), 6427
DOI 10.1038/s41467-021-26018-z, PubMed 34741021

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016

Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, Osbreac OBO, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2021)
Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
Cancers (Basel), 13 (23)
DOI 10.3390/cancers13236118, PubMed 34885228

Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864

Publications 2020

Ness C, Katta K, Garred Ø, Kumar T, Olstad OK, Petrovski G, Moe MC, Noer A (2020)
Integrated differential DNA methylation and gene expression of formalin-fixed paraffin-embedded uveal melanoma specimens identifies genes associated with early metastasis and poor prognosis
Exp Eye Res, 203, 108426
DOI 10.1016/j.exer.2020.108426, PubMed 33387485

Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909

Publications 2019

Debik J, Euceda LR, Lundgren S, Gythfeldt HVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF, Giskeødegård GF (2019)
Assessing Treatment Response and Prognosis by Serum and Tissue Metabolomics in Breast Cancer Patients
J Proteome Res, 18 (10), 3649-3660
DOI 10.1021/acs.jproteome.9b00316, PubMed 31483662

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Lai X, Geier OM, Fleischer T, Garred Ø, Borgen E, Funke SW, Kumar S, Rognes ME, Seierstad T, Børresen-Dale AL, Kristensen VN, Engebraaten O, Köhn-Luque A, Frigessi A (2019)
Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data
Cancer Res, 79 (16), 4293-4304
DOI 10.1158/0008-5472.CAN-18-1804, PubMed 31118201

Nome ME, Euceda LR, Jabeen S, Debik J, Bathen TF, Giskeødegård GF, Taskén KA, Maelandsmo GM, Halvorsen B, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X (2019)
Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers
Int J Cancer, 146 (1), 223-235
DOI 10.1002/ijc.32638, PubMed 31444972

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

Höglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred Ø, Holmen MM, Wist E, Naume B, Van Loo P, Børresen-Dale AL, Engebraaten O, Kristensen V (2018)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations
Genome Med, 10 (1), 92
DOI 10.1186/s13073-018-0601-y, PubMed 30497530

Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
J Thromb Haemost, 16 (7), 1347-1356
DOI 10.1111/jth.14151, PubMed 29766637

Publications 2017

Euceda LR, Haukaas TH, Giskeodegard GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred O, Postma G, Buydens LMC, Borresen-Dale AL, Engebraaten O, Bathen TF (2017)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DOI 10.1007/s11306-017-1168-0

Ness C, Garred Ø, Eide NA, Kumar T, Olstad OK, Bærland TP, Petrovski G, Moe MC, Noer A (2017)
Multicellular tumor spheroids of human uveal melanoma induce genes associated with anoikis resistance, lipogenesis, and SSXs
Mol Vis, 23, 680-694
PubMed 29033534

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL et al. (2017)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444

Vaysse C, Lomo J, Garred O, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husoy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer (vol 3, 35, 2017)
npj Breast Cancer, 3, 35
DOI 10.1038/s41523-017-0030-x

Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
NPJ Breast Cancer, 3, 19
DOI 10.1038/s41523-017-0015-9, PubMed 28649659

Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I (2017)
Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer
NPJ Breast Cancer, 3, 35
DOI 10.1038/s41523-017-0030-x, PubMed 28884144

Publications 2016

Flote VG, Vettukattil R, Bathen TF, Egeland T, McTiernan A, Frydenberg H, Husøy A, Finstad SE, Lømo J, Garred Ø, Schlichting E, Wist EA, Thune I (2016)
Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer
Lipids Health Dis, 15, 56
DOI 10.1186/s12944-016-0225-4, PubMed 26970778

Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF, Oslo Breast Cancer Consortium (OSBREAC) (2016)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
Cancer Metab, 4, 12
DOI 10.1186/s40170-016-0152-x, PubMed 27350877

Shlien A, Raine K, Fuligni F, Arnold R, Nik-Zainal S, Dronov S, Mamanova L, Rosic A, Ju YS, Cooke SL, Ramakrishna M, Papaemmanuil E, Davies HR, Tarpey PS, Van Loo P, Wedge DC, Jones DR, Martin S, Marshall J, Anderson E, Hardy C, ICGC Breast Cancer Working Group, Oslo Breast Cancer Research Consortium, Barbashina V, Aparicio SA, Sauer T et al. (2016)
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer
Cell Rep, 16 (7), 2032-46
DOI 10.1016/j.celrep.2016.07.028, PubMed 27498871

Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb Res, 145, 78-83
DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249

Publications 2015

Eide N, Garred Ø, Beiske K, Fodstad Ø (2015)
Bilateral uveal melanomas with different gene expression detected with 7 years interval
Acta Ophthalmol, 94 (1), 99-102
DOI 10.1111/aos.12857, PubMed 26496992

Publications 2014

Chen Y, Klingen TA, Wik E, Aas H, Vigeland E, Liestøl K, Garred Ø, Mæhlen J, Akslen LA, Lømo J (2014)
Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study
Diagn Pathol, 9, 230
DOI 10.1186/s13000-014-0230-8, PubMed 25522915

Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022

Publications 2007

Kurmanova A, Llorente A, Polesskaya A, Garred O, Olsnes S, Kozlov J, Sandvig K (2007)
Structural requirements for furin-induced cleavage and activation of Shiga toxin
Biochem Biophys Res Commun, 357 (1), 144-9
DOI 10.1016/j.bbrc.2007.03.110, PubMed 17407762

Publications 2006

Sauer T, Garred O, Lømo J, Naess O (2006)
Assessing invasion criteria in fine needle aspirates from breast carcinoma diagnosed as DICS or invasive carcinoma: can we identify an invasive component in addition to DCIS?
Acta Cytol, 50 (3), 263-70
DOI 10.1159/000325952, PubMed 16780019

Publications 2005

Sauer T, Beraki K, Noren T, Garred O, Naess O (2005)
EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization
Diagn Cytopathol, 33 (4), 228-32
DOI 10.1002/dc.20338, PubMed 16138375

Sauer T, Lømo J, Garred O, Naess O (2005)
Cytologic features of ductal carcinoma in situ in fine-needle aspiration of the breast mirror the histopathologic growth pattern heterogeneity and grading
Cancer, 105 (1), 21-7
DOI 10.1002/cncr.20735, PubMed 15593325

Publications 2001

Garred Ø, Rodal SK, van Deurs B, Sandvig K (2001)
Reconstitution of clathrin-independent endocytosis at the apical domain of permeabilized MDCK II cells: requirement for a Rho-family GTPase
Traffic, 2 (1), 26-36
DOI 10.1034/j.1600-0854.2001.020105.x, PubMed 11208166

Publications 2000

Llorente A, van Deurs B, Garred O, Eker P, Sandvig K (2000)
Apical endocytosis of ricin in MDCK cells is regulated by the cyclooxygenase pathway
J Cell Sci, 113 ( Pt 7), 1213-21
DOI 10.1242/jcs.113.7.1213, PubMed 10704372

Sandvig K, Llorente A, Rodal SK, Eker P, Garred O, Stahlhut M, van Deurs B (2000)
Apical macropinocytosis in polarized MDCK cells: regulation by N-ethylmaleimide-sensitive proteins
Eur J Cell Biol, 79 (7), 447-57
DOI 10.1078/0171-9335-00071, PubMed 10961444

Publications 1999

Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K (1999)
Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles
Mol Biol Cell, 10 (4), 961-74
DOI 10.1091/mbc.10.4.961, PubMed 10198050

Publications 1997

Garred O, Dubinina E, Polesskaya A, Olsnes S, Kozlov J, Sandvig K (1997)
Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells
J Biol Chem, 272 (17), 11414-9
DOI 10.1074/jbc.272.17.11414, PubMed 9111051

Garred Ø (1997)
Entry of Shiga toxin into cells: intracellular transport of protein toxins
Department of Biochemistry, Institute for Cancer Research, The Norwegian Radium Hospital, Medical Faculty, University of Oslo, [Oslo], 1 b. (flere pag.)
BIBSYS 972822852, ISBN 82-7633-099-1

Polesskaia AN, Garred O, Olsnes S, Kozlov IuV (1997)
[Self-inhibiting N-glycosidase activity of shigella toxin]
Mol Biol (Mosk), 31 (3), 528-35
PubMed 9297098

Polesskaya AN, Garred O, Olsnes S, Kozlov YV (1997)
Self-inhibition of N-glycosidase activity of shiga toxin
Mol. Biol., 31 (3), 441-447

Sandvig K, Garred O, van Deurs B (1997)
Intracellular transport and processing of protein toxins produced by enteric bacteria
Adv Exp Med Biol, 412, 225-32
DOI 10.1007/978-1-4899-1828-4_34, PubMed 9192018

Publications 1996

Llorente A, Garred O, Holm PK, Eker P, Jacobsen J, van Deurs B, Sandvig K (1996)
Effect of calmodulin antagonists on endocytosis and intracellular transport of ricin in polarized MDCK cells
Exp Cell Res, 227 (2), 298-308
DOI 10.1006/excr.1996.0279, PubMed 8831568

Sandvig K, Garred O, van Deurs B (1996)
Thapsigargin-induced transport of cholera toxin to the endoplasmic reticulum
Proc Natl Acad Sci U S A, 93 (22), 12339-43
DOI 10.1073/pnas.93.22.12339, PubMed 8901582

Sandvig K, Garred O, van Helvoort A, van Meer G, van Deurs B (1996)
Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells
Mol Biol Cell, 7 (9), 1391-404
DOI 10.1091/mbc.7.9.1391, PubMed 8885234

Publications 1995

Garred O, Dubinina E, Holm PK, Olsnes S, van Deurs B, Kozlov JV, Sandvig K (1995)
Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants
Exp Cell Res, 218 (1), 39-49
DOI 10.1006/excr.1995.1128, PubMed 7737376

Garred O, van Deurs B, Sandvig K (1995)
Furin-induced cleavage and activation of Shiga toxin
J Biol Chem, 270 (18), 10817-21
DOI 10.1074/jbc.270.18.10817, PubMed 7738018

Lanzrein M, Garred O, Olsnes S, Sandvig K (1995)
Diphtheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF precursor): studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-ester-treated cells
Biochem J, 310 ( Pt 1) (Pt 1), 285-9
DOI 10.1042/bj3100285, PubMed 7646457

Publications 1994

SANDVIG K, GARRED O, HOLM PK, VANDEURS B (1994)
ENTRY OF SHIGA TOXIN INTO CELLS
INT CONGR SER, 1072, 139-146

Sandvig K, Ryd M, Garred O, Schweda E, Holm PK, van Deurs B (1994)
Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP
J Cell Biol, 126 (1), 53-64
DOI 10.1083/jcb.126.1.53, PubMed 8027186

Publications 1993

Sandvig K, Dubinina E, Garred O, Prydz K, Kozlov JV, Hansen SH, Van Deurs B (1993)
Entry of Shiga toxin into cells
Zentralbl Bakteriol, 278 (2-3), 296-305
DOI 10.1016/s0934-8840(11)80846-7, PubMed 8347933

Sandvig K, Garred O, Holm PK, van Deurs B (1993)
Endocytosis and intracellular transport of protein toxins
Biochem Soc Trans, 21 ( Pt 3) (3), 707-11
DOI 10.1042/bst0210707, PubMed 8224494

Publications 1992

Sandvig K, Dubinina E, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B (1992)
Protein toxins: mode of action and cell entry
Biochem Soc Trans, 20 (4), 724-7
DOI 10.1042/bst0200724, PubMed 1487049

Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B (1992)
Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum
Nature, 358 (6386), 510-2
DOI 10.1038/358510a0, PubMed 1641040